Bispecific antibodies: The next wave of precision cancer therapy
Bispecific antibodies are a rapidly advancing class of therapeutics, offering a new level of precision in treating diseases like cancer.| Drug Discovery and Development
Bispecific antibodies are a rapidly advancing class of therapeutics, offering a new level of precision in treating diseases like cancer.| Drug Discovery and Development
Nektar Therapeutics stock skyrocketed 287% after rezpegaldesleukin hit all endpoints in atopic dermatitis trials, but ongoing litigation with Lilly could complicate matters.| Drug Discovery and Development
The phase 4 EVEREST study showed that Dupixent demonstrated superiority over Xolair in adults with chronic rhinosinusitis.| Drug Discovery and Development
Just over three-quarters of patients receiving Sanofi and Regeneron’s Dupixent achieved at least a 75% improvement in disease severity.| Drug Discovery and Development
